-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
KalVista Pharmaceuticals, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2015 to 2023.
- KalVista Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending January 31, 2024 was -$28.9 M, a 47.8% decline year-over-year.
- KalVista Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending January 31, 2024 was -$108 M, a 17.6% decline year-over-year.
- KalVista Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$92.1 M, a 8.66% decline from 2021.
- KalVista Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$84.8 M, a 85.1% decline from 2020.
- KalVista Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$45.8 M, a 57.5% decline from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)